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Introduction
Cathepsin K is an elastase that belongs to the papain-
cystein proteinase family and possesses an unique col-
lagenolytic activity [1]. It plays a well – known role in
bone turnover, but also in nonosseous lesions, possibly
through remodeling of the extracellular matrix [1]. Tis-
sue remodeling is crucial in different lung diseases, in
the embryonal development as well as in bronchial
carcinoma [2]. Cathepsin K is expressed by osteoclasts
and macrophages and in the lung by bronchial epithe-
lial and alveolar cells [3,4]. The role of cathepsin K in
neoplastic conditions is not fully understood. The
reports on prostate and breast carcinomas indicate that
cathepsin K may be produced by epithelial neoplastic
cells and that its expression is associated with the
increased invasive potential [5,6].  Rapa et al. [7]
demonstrate that Cath K is newly produced in the stro-
ma of invasive tumors of the lung and can favor or
modulate the invasive growth of tumor cells.  The
intracellular activity of Cath K is regulated by specific
endogenous cysteine proteinase inhibitors such as cys-
tatin C [8]. 
Cystatin C is a non-glycosylated low molecular
weight (13kD) basic protein that is produced by all
nucleated cells [9]. This protein is a member of the
cystatin superfamily of cysteine protease inhibitors;
the production rate of cystatin C is stable and does not
change in inflammatory  conditions [9]. Due to its
nature, the serum level of cystatin C is known to be a
better marker for GFR (glomerular filtration rate) than
serum creatinine [9]. Cystatin C is the most important
extracellular inhibitor of several cysteine proteinases,
and it has been postulated that the imbalance between
cysteine proteinases and cystatins can contribute to
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connective tissue remodeling [10]. Moreover, in
patients with colorectal cancer and malignant
melanoma, a significant correlation has been revealed
between the increased serum cystatin C level and
malignant progression [11]. High cystatin C levels
were associated with a tumor's size, postmenopausal
status and a patient's age [12]. There are no findings
about concentrations of Cath K and Cyst C in the
serum of lung cancer patients.  In our study, we meas-
ured the serum levels of Cath K and Cyst C in lung
cancer patients to assess their correlations and their
clinical significance.
Materials and methods
Patients. The study involved 40 patients diagnosed and treated in
the Department of Lung Diseases and Tuberculosis in Bialystok
(32 men and 8 women) with the histological diagnosis of NSCLC.
The mean age of patients was 61.7 ± 6 years (Patients' charac-
teristics is shown in Table 1). The study patients had neither been
treated with any anticancer medication nor undergone radiothera-
py. Squamous cell carcinoma (SCC) comprised 42.5% (17 individ-
uals) of patients with NSCLC, adenocarcinoma was revealed in
27.5% (11 patients), whereas NSCLC was diagnosed in 30% (12
patients). Serum samples, obtained from the whole blood of
patients with lung cancer before cytoreduction treatment and after
four cycles of chemotherapy, were used as the study material. To
exclude the possible interference of chemotherapy, subsequent
blood samples were obtained at least 28 days after the last admin-
istration of cytotoxic drugs. Blood serum was stored at -80°C
immediately after separation by centrifugation (3000 rpm) until the
assay was performed. At the first stage, blood samples were taken
to assess Cath K and Cyst C after complete diagnostics of lung
cancer had been made, including X-ray and CT of the chest, bron-
chofiberscopy with H+P examination lung transbronchial biopsy
(TBB), or transbronchial needle aspiration biopsy (TBNA). The
clinical analysis comprised the evaluation of clinical staging of
NSCLC (TNM, AJCC), and the performance stage according to
Zubrod. The response to therapy was estimated according to the
WHO criteria. All patients underwent basic laboratory tests and
accessory investigations (ultrasonography of the abdominal cavity,
if necessary, of the chest, EEG, and CT of the central nervous sys-
tem). At the next stage, after termination of chemotherapy, during
the evaluation of therapy outcome, blood samples were collected to
determine the concentrations of Cath K and Cyst C.
Controls. The control group consisted of 15 healthy volunteers (12
men and 3 women) without any acute or chronic inflammatory
conditions, without history of any kidney diseases, hypertension,
diabetes mellitus.  The mean age of controls at the time of sam-
pling was 62.1 ± 4 year. There were no significant differences in
age and sex between patients and controls.
Therapy. Chemotherapy was carried out in a 21-day cycle using
cisplatin at a dose of 30 mg/m2 on days 1, 2, and 3 and gemcytabine
at a dose of 1000 mg/m2 on days 1 and 8 of the cycle. All patients
received four cycles of chemotherapy. Some of the patients under-
went later radiotherapy or next cycles of chemotherapy.
Serum Cath K and Cyst C analysis. Cathepsin K (Cathepsin K
Elisa Kit, Biomedica Austria), cystatin C (Human Cystatin C
Quantikine ELISA Kit, R&D System, USA) concentrations were
determined by means of an enzyme-linked immunosorbent assay
(ELISA) method according to the manufacturer's instructions. All
specimens were assayed in duplicates. The detection limit of Cath
K was 1.1 pmol/l (0 pmol/l + 3 SD). The median range was 8.7
pmol/l. The standard range was from 0 pmol/l to 300 pmol/l. The
minimum detectable dose (MDD) of cystatin C ranged from 0.030
– 0.227 ng/ml. The mean MDD was 0.102 ng/ml. 
Ethical issues. In accordance with the declaration of Helsinki, the
study protocol was approved by the local ethics committee and a
written informed consent was obtained from all participants.
Statistical analysis. Statistical analysis was performed using
Statistica 8.0 software (Stat Soft Inc., Tulsa, USA). The compat-
ibility test of  Shapiro-Wilk was used for measurable features
consistent with normal distribution. The Student t test was
applied to compare the respective groups and for  pairs to com-
pare features in two time intervals. Correlations between the
parameters were calculated by the Pearson's tests. Survival
curves were made using the Kaplan-Meier method, and the sig-
nificance of the difference in survival rates was determined by
the log-rank test. Multivariate analysis was performed using the
Cox proportional hazards model. All patients with lung cancer
were divided into two groups according to their Cath K and Cyst
C serum levels. The cut-off point was set at 23.35 pmol/l for Cath
K, and 1.29 mg/l for Cyst C. Receiver-operating characteristics
(ROC) curves were applied to find the cut-off level of Cath K and
Cyst C. A value of p<0.05 was considered to be the level of sta-
tistical significance.
Results
None of the prognostic parameters analyzed  (Table  1)
was correlated significantly with the serum Cath K and
Cyst C  levels (p>0.05).
The levels of serum Cath K and Cyst C  in patients
with advanced NSCLC and healthy controls are shown
in Table 2. The baseline serum Cyst C levels were sig-
nificantly higher in patients with advanced NSCLC
than in the control group (p=0.003). Cath K levels
were not significantly different from healthy control
group (p=0.976).  Concentrations of Cath K and Cyst
C  did not differ markedly before and after chemother-
apy of lung cancer (p=0.539, p=0.751).  No correlation
was found between Cath K and Cyst C  concentrations
and the histological type and staging of lung cancer.
Patients in group IIIB had the same concentrations of
Cath K and Cyst C as patients in group IV. However,
the patients with T4-stage had lower level of Cyst C
(after chemotherapy) than those with T2 (p=0.033)
(Fig. 1). 
In the study group, PR (partial response) was
reported in 16 patients (40%), stabilization (NC, no
change) in 10 patients (25%), and PD (progressive dis-
ease) in 14 patients (35%). No correlation was found
between the concentrations of Cath K and Cyst C  and
the effect of chemotherapy (Tables 3 and 4).
There was no correlation between serum levels of
Cath K and Cyst C.  A positive correlation was
revealed between serum creatinine and serum Cyst C
in patients who responded to chemotherapy (PR, NC)
(R=0.535; p=0.005) (Fig. 2); between serum Cyst C
and age of patients (R=0.456; p=0.018).  
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When all patients with lung cancer were divided
into high and low groups using cut-off serum Cath K
and Cyst C  concentrations, the prognoses of high and
low groups were not different. The cut-off serum con-
centrations were 23.35 pmol/l (Cath K) (Fig. 3), and
1.29 mg/l (Cyst C) (Fig. 4). The median survival of the
study  group was 11.3 months. Older age, weight loss,
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Table 1. Patients' characteristics. 
Abbreviations: n – number; SD – standard deviation; eGFR – MDRD –
estimated Glomerular Filtration Rate according to Modified Diet in Renal
Diseases 
Fig. 1. The serum levels of Cystatin C after chemotherapy in
groups of T4 and T2 (according to TNM) patients by Student's T –
test for unpaired samples.Table 2. Distribution of serum Cath K and Cyst C values in
patients with NSCLC and healthy controls by Student's T – test for
unpaired samples.
Abbreviations: n – number; SD – standard deviation
Fig. 2. Relationship between Serum Crea-
tinine and Serum Cystatin C in patients
who responded to chemotherapy (Partial
Response + No Change). 
and performance status yielded a prognostic value
(Table 5). Conversely, neither Cath K nor Cyst C  lev-
els were proved  to be significant for survival.
ROC (Receiver Operating Characteristic) curve
was analyzed to assess the effectiveness of serum Cath
K and Cyst C  determination  in discrimination
between NSCLC and controls (Fig. 5). The AUCs of
Cath K and Cyst C  were 0.485 and 0.588. ROC curves
showed a poor clinical performance of Cyst C in the
detection of NSCLC patients. The cut off values of
Cath K and Cyst C  were established at 8.72 pmol/l and
1.24 mg/l, respectively. There were no significant dif-
ferences between the areas under the curves.
Discussion
Although cathepsin K has a well-defined function in
inflammation, bone remodeling, macrophage activity,
and lung fibrosis, its role in neoplastic growth has not
been explained completely.
There have been no findings on serum concentra-
tions of Cath K patients with lung cancer. Cath K
expression in  macrophages, in the lung by bronchial
epithelial and alveolar cells, and in the stroma of
NSCLC  suggested higher serum concentrations of
Cath K patients with lung cancer than in healthy people.
According to  Kleer et al. [13] Cath K plays a role in
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Fig. 3. Probability of survival for lung
cancer patients in relation to serum
Cath K levels (before chemotherapy) 
Fig. 4. Probability of survival for lung
cancer patients in relation to serum
Cyst C levels (before chemotherapy) 
tumor progression by promoting extracellular matrix
degradation  and angiogenesis as well as  by increasing
the invasiveness or neighboring tumor epithelial cells.
Moreover, the relation between the  enhanced secretion
of  Cyst C, an inhibitor of Cath K,  and the  invasive
potential has been found in various cell lines [14].
In this study we proved that patients with advanced
NSCLC had similar Cath K concentrations to those in
healthy people, but higher concentrations of  Cystatin C.
Our results are partially in accordance with   Tumello's
et al. findings [8].  These authors found higher Cyst C
concentrations in patients with breast cancer, whereas
Cath K concentrations were lower. In patients with
prostate cancer, Cath K concentrations were the same as
in healthy people [8]. It is known that in the intracellu-
lar environment, Cath K activity is inhibited by  Cyst C
and its expression by epithelial neoplastic cells  is asso-
ciated  with an increase in the invasive potential [5,6]. It
is likely that Cyst C and other antiproteases contribute
to a decrease in Cath K concentration to the same or
even lower levels when compared to healthy people. 
In our study, the increased levels of Cyst C  do not
seem to be caused by an impaired kidney function as
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Fig. 5. ROC curves of Cath K and Cyst C (for
discrimination between NSCLC and controls)
Table 3. Distribution of serum values of Cath K and Cyst C before
and after chemotherapy, in patients with partial response or stable
disease by Student's T – test for paired samples (subgroup analysis). 
Abbreviations: n- number; SD- standard deviation 
Table 4. Distribution of serum values of Cath K and Cyst C before
and after chemotherapy, in patients with progressive disease by
Student's T – test for paired samples (subgroup analysis). 
Abbreviations: n- number; SD- standard deviation 
Table 5. Influence of statistically significant prognostic factors
and serum parameters on survival in advanced NSCLC patients
none of these patients showed a clinically evident
alteration in the renal functioning.  The concentration
of Cyst C was proved to correlate with the concentra-
tion of creatinine in serum of the study patients with
partial remission or stabilization after treatment. No
correlation was revealed in patients with progression,
in whom cancer cells are the main source of  Cyst C in
serum. In these patients, the determination of cystatin
C  as GFR marker is not useful, which confirms
Nakai's  et al. studies  [9]. These authors found that
serum levels of cystatin C were  not always a reliable
marker of renal efficiency in patients with a malignancy.
Cystatin C is synthesized by all nucleated cells. It
has been suggested that cystatin C might be overex-
pressed in tumor cells, resulting in increased circulat-
ing levels [15]. Moreover, cystatin C is thought to play
a role in protein homeostasis in the extracellular com-
partment, inhibiting inappropriate hydrolytic degrada-
tion by proteinases released from dying cells [16].
Cystatin C may also be released from infiltrated
inflammatory cells such as macrophages and neu-
trophils [17]. Higher serum concentrations of Cyst C
were also determined in patients with  ovarian cancer
[18], colorectal cancer  and melanoma  [19] in com-
parison with healthy people.  The results of our study
carried out among patients with lung cancer are in
agreement with findings mentioned above. However,
the clinical usefulness of cystatin C determination in
serum (as well as of Cath K) is poor, which was proved
by means of  ROC curves . 
Findings on Cyst C activity in serum with regard to
cancer staging are controversial. In our study, patients
at the stage  III B had identical concentrations to those
of patients at the stage IV. The results of our study are
confirmed by Dreilich's et al. studies  [19] based on
patients with esophagus cancer.
According to Werle and Kos [14,17] higher total
concentrations of Cyst C found in sera of patients with
lung, colorectal and melanoma cancer  suggested the
enhanced secretion of cystatin C from tumor cells,
increasing at the same time the intracellular proteolyt-
ic potential of  cysteine proteases. Moreover, increased
levels of cystatin C in tumor tissues have been shown
to correlate with favorable prognosis of cancer patients
[20- 22]. High concentrations of Cyst C may inhibit
proteases activity (including Cath K) and  the growth
of a tumor, which was confirmed by Strojan's et al.
study [14]. They observed in patients with carcinoma
of the head and neck, an inverse correlation between
tumor cystatin C level and a more aggressive form of
the disease. Our study is in accordance with the find-
ings mentioned above. We indicated that patients with
T2 – stage had higher concentration of Cyst C than
patients with T4- stage. The low level of Cyst C in
patients with T4-stage in our study may suggest a pos-
sibility of consumption or inactivation of Cyst C in the
course of tumor growth.  Our study confirmed Nakai's
et al. findings [9], demonstrating that in coloncancer
sera, the level of Cyst C was lower in advanced stages
than in early stages. On the other hand,  Kos at al
found in the study group with colorectal cancer,  the
patients with high serum levels of Cyst C  exhibited a
higher risk of death (due to rapid growth of a tumor)
than those with lower levels of an inhibitor [23]. In our
study, no correlations were demonstrated between con-
centrations of Cyst C and  Cath K, and survival time.
Our observations are similar to Werle's et al. results of
the studies in patients with NSCLC [17]. 
These various results obtained in studies of partic-
ular cancers may be due to the complexity of mecha-
nisms influencing Cyst C concentration in serum.
However, cysteine proteases (and also Cath K), and
consequently their inhibitors, are involved in various
physiological processes, including those which may
act in an opposite way to a tumor's progression, such
as apoptosis, activation of the T-cell immune response,
as well as cell migration and seeding [24-27]. Thus,
besides their concentration, the cell and tissue local-
ization of Cyst C and Cath K could also make a criti-
cal switch between harmless and harmful. 
Summarizing,  it has been proved that cystatin C
concentration is higher in patients with advanced
NSCLC than in healthy people, whereas  Cathepsin K
concentration is comparable. Determination of
Cathepsin K and Cyst C concentrations is not useful  in
monitoring therapy effects of NSCLC predicting sur-
vival time. Cyst C concentration decreases together
with the growth of a tumor's size. 
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